- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07700069
Acupuncture Versus Sham Acupuncture for Tinnitus
Efficacy and Safety of Acupuncture Versus Sham Acupuncture in the Treatment of Tinnitus: A Randomized Controlled Clinical Trial
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Subjective idiopathic tinnitus is a common otologic condition that may be associated with sleep disturbance, anxiety, depression, and reduced quality of life. Current treatment options often provide limited symptom relief, and high-quality evidence for acupuncture in tinnitus remains insufficient.
This study is designed as a multicenter, randomized, sham-controlled clinical trial to compare acupuncture with non-penetrating sham acupuncture in patients with chronic subjective idiopathic tinnitus. Eligible participants will be adults aged 18 to 80 years with tinnitus as the primary complaint, tinnitus duration of at least 6 months, and a baseline Tinnitus Handicap Inventory score of 38 or higher.
Participants will be randomly assigned in a 1:1 ratio to the acupuncture group or the sham acupuncture group. The acupuncture group will receive standardized acupuncture treatment based on the therapeutic principle of invigorating the spleen, tonifying the kidney, and opening the orifices. The sham acupuncture group will receive non-penetrating sham acupuncture at the same acupoints. Both groups will receive treatment for 5 weeks and tinnitus-related health education.
Participants will be assessed at baseline, during treatment, at the end of treatment, and during post-treatment follow-up. The primary endpoint is the change in Tinnitus Handicap Inventory score from baseline to Week 5. Secondary outcomes include tinnitus-related visual analog scale scores, Pittsburgh Sleep Quality Index, Self-Rating Anxiety Scale, Self-Rating Depression Scale, pure tone audiometry, tinnitus matching, distortion product otoacoustic emissions, and adverse events. Exploratory outcomes include changes in brain functional connectivity measured by functional magnetic resonance imaging and brain power spectral density measured by magnetoencephalography.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Yun Li, MD
- Telefonnummer: 0086-021-63138341
- E-post: liyuncmm@126.com
Studieorter
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200437
- Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
-
Kontakt:
- Ling J Zhang, PHD
- Telefonnummer: 0086-021-65161782
- E-post: eternityz@sina.com
-
Huvudutredare:
- Ying J Tan, MD
-
Shanghai, Shanghai Municipality, Kina, 200011
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
-
Kontakt:
- Yun Li, MD
- Telefonnummer: 0086-021-021-63138341
- E-post: liyuncmm@126.com
-
Huvudutredare:
- Yu G Liu, PHD
-
Shanghai, Shanghai Municipality, Kina, 200032
- Longhua Hospital, Shanghai University of Traditional Chinese Medicine
-
Kontakt:
- Hui J Lan, MD
- Telefonnummer: 0086-021-64385700
- E-post: lanjh_ent@163.com
-
Huvudutredare:
- Hui J Lan, MD
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Tinnitus as the primary complaint, meeting the diagnostic criteria for subjective idiopathic tinnitus.
- Tinnitus duration of at least 6 months.
- Patent external auditory canal and intact tympanic membrane.
- Bilateral pure tone average no greater than 80 decibels hearing level (dB HL).
- No contraindications to MRI or MEG scanning, such as claustrophobia or metallic implants.
- Age 18 to 80 years.
- Right-handed.
- Baseline Tinnitus Handicap Inventory score of 38 or higher.
- Able to understand and complete examinations, assessments, and treatment procedures under physician guidance.
- Willing to participate and able to provide written informed consent before treatment.
Exclusion Criteria:
- Inner ear or auditory nerve disorders, including sudden sensorineural hearing loss, Meniere disease, otosclerosis, or acoustic neuroma.
- External or middle ear diseases, including otitis externa, foreign body in the external auditory canal, eczema of the external auditory canal, cerumen impaction, acute or chronic otitis media with effusion, or acute or chronic suppurative otitis media.
- Non-otogenic tinnitus caused by acute or chronic systemic diseases involving hematologic, endocrine, renal, or other major organ systems.
- Objective tinnitus, including myogenic, vascular, or patulous eustachian tube-related tinnitus.
- Cognitive impairment or tinnitus caused by other neurological diseases, including stroke, epilepsy, traumatic brain injury, severe headache history, severe central ischemia, brain tumor, neurasthenia, or post-neurosurgical tinnitus.
- Severe cardiovascular or cerebrovascular disease, intracranial space-occupying disease, tumor, or severe pulmonary, hepatic, renal, or hematopoietic disease.
- Pregnancy or lactation.
- Psychiatric disease, impaired consciousness, or inability to cooperate with examinations or treatment.
- Participation in another conflicting clinical trial within 6 months before enrollment or currently participating in another conflicting clinical trial.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Acupuncture
Participants in this arm will receive standardized acupuncture treatment twice weekly for 5 consecutive weeks, with 10 sessions in total.
Acupuncture will be performed at Tinghui (GB2), Shuaigu (GB8), Taixi (KI3), Taibai (SP3), Yifeng (TE17), and Zhigou (TE6).
Needles will be retained for 20 minutes.
Participants will also receive tinnitus-related health education.
|
Standardized acupuncture treatment will be administered twice weekly for 5 consecutive weeks, with 10 sessions in total.
Acupuncture will be performed at Tinghui (GB2), Shuaigu (GB8), Taixi (KI3), Taibai (SP3), Yifeng (TE17), and Zhigou (TE6).
Needles will be inserted according to standardized acupoint locations and retained for 20 minutes.
Participants will also receive tinnitus-related health education.
|
|
Sham Comparator: Sham Acupuncture
Participants in this arm will receive non-penetrating sham acupuncture twice weekly for 5 consecutive weeks, with 10 sessions in total.
The same acupoints as the acupuncture group will be used.
Blunt-tip needles will contact the skin surface without skin penetration or manual needle manipulation.
Needles will be retained for 20 minutes.
Participants will also receive tinnitus-related health education.
|
Non-penetrating sham acupuncture will be administered twice weekly for 5 consecutive weeks, with 10 sessions in total.
The same acupoints as the acupuncture group will be used.
Blunt-tip needles will contact the skin surface without skin penetration or manual needle manipulation.
Needles will be retained for 20 minutes.
Participants will also receive tinnitus-related health education.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Tinnitus Handicap Inventory Score From Baseline to Week 5
Tidsram: Baseline and Week 5
|
The Tinnitus Handicap Inventory is a 25-item questionnaire used to assess tinnitus-related handicap.
The total score ranges from 0 to 100, with higher scores indicating more severe tinnitus-related handicap.
The primary outcome is the change in Tinnitus Handicap Inventory score from baseline to Week 5.
|
Baseline and Week 5
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Pittsburgh Sleep Quality Index Score
Tidsram: Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
The Pittsburgh Sleep Quality Index is used to assess sleep quality.
Higher scores indicate poorer sleep quality.
The change from baseline will be compared between the acupuncture and sham acupuncture groups.
|
Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
|
Change in Tinnitus Loudness Visual Analog Scale Score
Tidsram: Baseline, immediately after the first treatment session, Week 1, Week 3, Week 5, Week 9, and Week 17
|
The tinnitus loudness visual analog scale is used to assess perceived tinnitus loudness.
Higher scores indicate greater tinnitus loudness.
The change from baseline will be compared between groups.
|
Baseline, immediately after the first treatment session, Week 1, Week 3, Week 5, Week 9, and Week 17
|
|
Change in Tinnitus Severity Visual Analog Scale Score
Tidsram: Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
The tinnitus severity visual analog scale is used to assess the subjective severity or impact of tinnitus.
Higher scores indicate greater tinnitus-related severity or impact.
The change from baseline will be compared between groups.
|
Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
|
Change in Self-Rating Anxiety Scale Score
Tidsram: Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
The Self-Rating Anxiety Scale is used to assess anxiety symptoms.
Higher scores indicate more severe anxiety symptoms.
The change from baseline will be compared between groups.
|
Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
|
Change in Self-Rating Depression Scale Score
Tidsram: Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
The Self-Rating Depression Scale is used to assess depressive symptoms.
Higher scores indicate more severe depressive symptoms.
The change from baseline will be compared between groups.
|
Baseline, Week 1, Week 3, Week 5, Week 9, and Week 17
|
|
Change in Pure Tone Audiometry Thresholds
Tidsram: Baseline ,week1, Week 5
|
Pure tone audiometry will be used to assess hearing thresholds.
The change from baseline will be compared between the acupuncture and sham acupuncture groups.
|
Baseline ,week1, Week 5
|
|
Change in Tinnitus Matching Loudness
Tidsram: Baseline ,week1, Week 5
|
Tinnitus matching loudness will be assessed using audiological testing.
The change from baseline will be compared between groups.
|
Baseline ,week1, Week 5
|
|
Change in Distortion Product Otoacoustic Emissions
Tidsram: Baseline ,week1, Week 5
|
Distortion product otoacoustic emissions will be used to evaluate cochlear outer hair cell function.
The change from baseline will be compared between groups.
|
Baseline ,week1, Week 5
|
|
Incidence of Adverse Events
Tidsram: From baseline through Week 17
|
All adverse events and treatment-related adverse events will be recorded throughout the study.
The incidence of adverse events will be compared between the acupuncture and sham acupuncture groups.
|
From baseline through Week 17
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Magnetoencephalography (MEG) Power Spectral Density
Tidsram: Baseline, after the first treatment session, and Week 5
|
Magnetoencephalography will be used as an exploratory neuroimaging outcome to assess changes in brain power spectral density from baseline.
|
Baseline, after the first treatment session, and Week 5
|
|
Change in Functional Magnetic Resonance Imaging (fMRI) Functional Connectivity
Tidsram: Baseline and Week 5
|
Functional magnetic resonance imaging will be used as an exploratory neuroimaging outcome to assess changes in brain functional connectivity from baseline.
|
Baseline and Week 5
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Yun Li, MD, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SH9H-2026-T202-1
- 2025CROC07 (Annat bidrag/finansieringsnummer: Shanghai Ninth People's Hospital)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .